Terumo sets sights on European DES (drug-eluting stent) market
This article was originally published in Clinica
Japanese medtech company Terumo is venturing into the competitive drug-eluting stent (DES) market in Europe. Plans are underway to launch the firm's Biolimus A-9 eluting stent, licensed from Singapore-based Biosensors International, on the continent in the second half of the next fiscal year.
You may also be interested in...
Emerging Company Profile: Axcella uses Generally Recognized As Safe (GRAS) amino acids to create drug candidates for hepatic encephalopathy, NASH and other diseases.
A reagent in a batch of COVID-19 tests shipped by the US Centers for Disease Control and Prevention to state laboratories “wasn’t performing consistently,” a top CDC official says, so the agency is reformulating it – slowing down the labs’ ability to use the diagnostic, which yielded inconsistent results when quality-tested. But waiting in the wings are commercial coronavirus test kits being developed by Qiagen and Cepheid; both firms say they’ll submit the kits to the FDA for emergency-use approval.
OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.